Skip to main content
. Author manuscript; available in PMC: 2017 Nov 6.
Published in final edited form as: Curr Drug Targets. 2016;17(15):1747–1754. doi: 10.2174/1389450117666151209123544

Fig. 3. Breakdown of the models used to study preclinical VEGF pathway inhibitor resistance in the papers selected for analysis.

Fig. 3

A) Distribution of papers involving in vitro and in vivo derivation of resistance. B) Number of papers involving derivation of resistant tumor or non-tumor cells in vitro. C) Number of papers involving in vivo derivation of resistance in implanted tumor and spontaneous disease models. D) Distribution of papers studying resistance in vivo involving ectopic and orthotopic tumor implantation models. E) Distribution of papers studying resistance in vivo involving xenograft and syngeneic tumor implantation models. F) Number of papers involving derivation of resistance models based on treatment of localized primary tumor or metastatic disease. Note: Gray areas represent papers that belong to both groups. Numbers in parenthesis correspond to numbers of papers in each group.